Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Obecabtagene autoleucel (obe-cel)
Obecabtagene autoleucel · 3 trials · 3 indications
CRR is a composite endpoint
Percentage of patients receiving obe-cel who experience dose-limiting toxicities (DLTs)
Adverse event (AE) type, frequency, severity, and relationship with obe-cel and lymphodepletion of AEs
| Arm | Type | Description |
|---|---|---|
| Obe-cel | EXPERIMENTAL | - |
| Obecabtagene autoleucel (obe-cel) | EXPERIMENTAL | - |
| AUTO1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Obecabtagene autoleucel | BIOLOGICAL | Obecabtagene autoleucel (obe-cel) given as a single infusion |
| Obecabtagene autoleucel (obe-cel) | BIOLOGICAL | Obecabtagene autoleucel (obe-cel) given as a single infusion. |
Inclusion Criteria: * Willing and able to give written informed consent for participation in the study or written informed consent signed by a legal guardian or representative * Ability and willingness to adhere to protocol's Schedule of Activities and other requirements * Participants must be 12 t...
Obecabtagene autoleucel, also known as obe-cel, is an investigational therapy being studied for systemic lupus erythematosus, progressive multiple sclerosis, and lupus nephritis. It is a CD19-targeting binding agent under development by Autolus Therapeutics plc (AUTL) for these autoimmune and neurologic conditions.
Obecabtagene autoleucel targets CD19, a protein found on B cells. By binding to CD19, the therapy is designed to deplete B cells involved in autoimmune diseases. This mechanism is being evaluated in clinical trials for systemic lupus erythematosus, lupus nephritis, and progressive multiple sclerosis.
Obecabtagene autoleucel is developed by Autolus Therapeutics plc, a biopharmaceutical company traded on the NASDAQ under the ticker AUTL. The company is conducting clinical trials of obe-cel in multiple countries for severe autoimmune and neurologic conditions.
Obecabtagene autoleucel is in Phase 2 clinical development for lupus nephritis, with an active Phase 1 trial in systemic lupus erythematosus and another Phase 1 trial in progressive multiple sclerosis. It is investigational and not yet approved by regulatory authorities.
Obecabtagene autoleucel is being studied in three trials: NCT06333483 in systemic lupus erythematosus (Phase 1, active not recruiting), NCT07053800 in lupus nephritis (Phase 2, recruiting), and NCT07139743 in progressive multiple sclerosis (Phase 1, recruiting). These trials are open in the US, UK, Spain, Brazil, Greece, and Vietnam.
Yes, Obecabtagene autoleucel is also known as obe-cel. The shorter name is used in clinical trial titles and medical literature. Both names refer to the same investigational CD19-targeting therapy developed by Autolus Therapeutics.